USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE
https://doi.org/10.14412/1995-4484-2011-58
Abstract
Small bowel (SB) injury is a common complication from the use of nonsteroidal anti-inflammatory drugs (NSAIDs). According to clinical trials, selective cyclooxygenase-2 inhibitors are safer in this respect. Meloxicam belongs to selective NSAIDs; however, its effect on the SB has been inadequately investigated.
Objective: to compare the effects of meloxicam 15 mg/day and diclofenac 150 mg/day on the SB mucosa.
Subjects and methods. A study group comprised 15 patients, including 6 men and 9 women (mean age 42.3+17.1 years), with ankylosing spondylarthritis (AS); 7 of them took meloxicam 15 mg/day for at least one month and 8 had diclofenac 100-150 mg/day. The SB was evaluated from capsule endocopy (CE) readings.
Results. SB erosions (n = 3 to 20 or more) were found in 11 patients: 5 (71.3%) and 6 (75.0%) subjects taking meloxicam and diclofenac, respectively (p = 0.82). The average amount of erosions in those receiving meloxicam (6.2+4.7) was less than in those having diclofenac (9.4+7.3; p = 0.13). One patient taking diclofenac was suspected of having Crohn's disease shown by CE and then confirmed by colonoscopy. Conclusion. Meloxicam has demonstrated a less negative effect than diclofenac on SB, although this difference was statistically insignificant. Small and bowel pathology frequently occurs in patients with AS and may be associated not only with the negative effect of the drugs, but also with comorbid inflammatory bowel diseases. There is a need for further studies of the distal gastrointestinal tract and for those of the effect of NSAIDs on the SB.
Objective: to compare the effects of meloxicam 15 mg/day and diclofenac 150 mg/day on the SB mucosa.
Subjects and methods. A study group comprised 15 patients, including 6 men and 9 women (mean age 42.3+17.1 years), with ankylosing spondylarthritis (AS); 7 of them took meloxicam 15 mg/day for at least one month and 8 had diclofenac 100-150 mg/day. The SB was evaluated from capsule endocopy (CE) readings.
Results. SB erosions (n = 3 to 20 or more) were found in 11 patients: 5 (71.3%) and 6 (75.0%) subjects taking meloxicam and diclofenac, respectively (p = 0.82). The average amount of erosions in those receiving meloxicam (6.2+4.7) was less than in those having diclofenac (9.4+7.3; p = 0.13). One patient taking diclofenac was suspected of having Crohn's disease shown by CE and then confirmed by colonoscopy. Conclusion. Meloxicam has demonstrated a less negative effect than diclofenac on SB, although this difference was statistically insignificant. Small and bowel pathology frequently occurs in patients with AS and may be associated not only with the negative effect of the drugs, but also with comorbid inflammatory bowel diseases. There is a need for further studies of the distal gastrointestinal tract and for those of the effect of NSAIDs on the SB.
References
1. <div><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.: Анко, 2000;142 с.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009;167 с.</p><p>Каратеев А.Е., Насонова В.А. Энтеропатия, индуцированная нестероидными противовоспалительными препаратами. Тер арх 2003;5:74-8.</p><p>Allison M., Howatson A., Torrance C. et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drags. N Engl J Med 1992;327:749-54.</p><p>Davies N., Saleh J., Skjodt N. Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci 2000; 3:137-55</p><p>Lang J., Price A., Levi A. et al. Diaphragm disease: the pathology of non-steroidal anti-inflammatory drug induced small intestinal strictures. J Clin Pathol 1988;41:516-26.</p><p>Adebayo D., Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006; 82(965):186-91</p><p>Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369:465-73.</p><p>Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173-9.</p><p>Delvaux M., Gay G. Capsule endoscopy: technique and indications. Best Pract Res Clin Gastroenterol 2008;22(5):813-37.</p><p>Qvigstad G., Hatlen-Rebhan P., Brenna E., Waldum H. Capsule endoscopy in clinical routine in patients with suspected disease of the small intestine: a 2-year prospective study. Scand J Gastroenterol 2006; 41(5):614-8.</p><p>Imaeda H., Ogata H., Iwao Y. et al. Expectation of video capsule endoscopy for diagnosis of NSAID induced enteropathy. Nippon Rinsho 2007;65(10):1896-901. '</p><p>Maiden L., Thjodleifsson B., Seigal A. et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5(9):1040-5.</p><p>Goldstein J., Eisen G., Lewis B. et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133-41.</p><p>Hawkey C., Ell C., Simon B. et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008;6(5):536-44.</p><p>Dougados M., Simon P., Braun J. et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70(2):249-51.</p><p>Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular tromboembolic complications with meloxicam. Am J Med 2004; 117:100-6.</p><p>Bernstein C., Blanchard J., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001;96(4):1116-22.</p><p>Larsen S., Bendtzen K., Nielsen O. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010; 42(2):97-114.</p><p>M., Gueguen A., Nakache J. et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999;38(3):235-44.</p><p>Mielants H., Veys E., Cuvelier C., de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988;27(Suppl. 2):95-105.</p><p>Mielants H., Veys E. Significance of intestinal inflammation in the pathogenesis of spondylarthropathies. Verh K Acad Geneeskd Belg 1996;58(2):93-116.</p><p>Grandbois L., Lomasney L., Demos T., Tehrani R. Radiologic case study. Seronegative spondyloarthropathy associated with Crohn's disease. Orthopedics 2005; 28(11):1296;1375-9.</p><p>Rudwaleit M., Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006;20(3):451-71.</p><p>Turkcapar N., Toruner M., Soykan I. et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006;26(7):663-8.</p></div><br />
Review
For citations:
Karateev A.E., Bochkova A.G., Rumyantseva O.A., Tyukhova E.Yu., Nasonov E.L. USE OF CAPSULE ENDOSCOPY TO EVALUATE THE EFFECTS OF MELOXICAM AND DICLOFENAC ON THE SMALL BOWEL MUCOSA IN PATIENTS WITH ANKYLOSING SPONDYLITIS: THE FIRST EXPERIENCE. Rheumatology Science and Practice. 2011;49(4):31-35. (In Russ.) https://doi.org/10.14412/1995-4484-2011-58
Views:
858
Email this article 